Product Hopping, Evergreening, Patent Thickets – A story of Sharply Diverging Views

2:30 PM - 3:45 PM, Monday, June 8, 2020 ・ Room 1B
There is much talk about so-called product hopping, evergreening, and patent thickets – practices that are said to be used by the pharmaceutical industry to extend outsized profit streams of old products instead of inventing new drugs. What is meant by these terms, what is their effect on generic drug entry, and what exactly are originator companies being accused of?
We will shed light on the question of how many patents there typically are for a new drug, when these patents are filed and issued and what they cover, and the effect they have on generic drug approval and market entry.
We will also discuss the role of continuing product development, such as new formulations, medical uses, and improved manufacturing of originator drug products and their implications for follow-on competitors in the biosimilar or generic drug market. Where is the line between bad tricks, legitimate interests in protecting innovation, and pro- and anti-competitive practices, and who draws that line?
Boehmert & Boehmert law firm
Senior Managing Director, Biotechnology Equity Research
Evercore ISI